Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Identification of Proteins Required for Small Extracellular Vesicle Fusion with Target Cells for Oligonucleotide Therapeutic Delivery
EF 2021-22
Résumé
Many
new therapies for diseases use molecules that silence genes that cause
these diseases. Despite this being a rising area in science, a significant
impediment in its utility is that it is challenging to get these molecules
into the cells to impart their effects. Even the best delivery methods,
such as the lipid nanoparticles (package made out of lipids that carry
biomolecules), which are the basis of COVID-19 vaccines, only deliver a
minimal amount of the molecule contained within them to the cell.
Furthermore, the lipid nanoparticles are relatively toxic to other organs,
and they have limited use in the context of many other diseases. A
new delivery method using small extracellular vesicles (package of
molecules made by the cell) has emerged to deliver these silencing
molecules over a long distance and into target cells. In the lab of Dr.
Derrick Gibbings, it has been shown that these vehicles can provide
50-100% of the silencing molecules that they contain into the cells. It is
proposed that the membrane of the small extracellular vesicle and the
target cell's membrane will fuse using different proteins, and then the
contents will mix. Identifying these proteins required for the fusion will
aid in discovering a new cellular mechanism that can be manipulated to
improve the delivery of the treatments. I
will be looking at different membrane proteins and seeing which ones are
vital in the fusion process of the membranes by finding genes that encode
for the protein and then shutting them off to see how that affects the
fusion. Ultimately, this will allow us to unravel the intricacies of the
fusion event, which will then provide the foundation in engineering these
small extracellular vesicles or any other delivery mechanisms to enhance
the delivery of therapeutics.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
475261
Name
Valentino Nicholas A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of Proteins Required for Small Extracellular Vesicle Fusion with Target Cells for Oligonucleotide Therapeutic Delivery
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crispr; Exosomes; Extracellular Vesicles; Gene Silencing; Mrna; Oligonucleotide Therapeutics; Rna Interferenace; Sirna; Systemic Delivery
Abstract
<html>
<head>
</head>
<body>
<span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none"><font color="rgb(0, 0, 0)" face="Verdana, Arial, Helvetica, sans-serif" size="12.8px">Many
new therapies for diseases use molecules that silence genes that cause
these diseases. Despite this being a rising area in science, a significant
impediment in its utility is that it is challenging to get these molecules
into the cells to impart their effects. Even the best delivery methods,
such as the lipid nanoparticles (package made out of lipids that carry
biomolecules), which are the basis of COVID-19 vaccines, only deliver a
minimal amount of the molecule contained within them to the cell.
Furthermore, the lipid nanoparticles are relatively toxic to other organs,
and they have limited use in the context of many other diseases.</font></span><font color="rgb(0, 0, 0)" face="Verdana, Arial, Helvetica, sans-serif" size="12.8px"><br align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"><br align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"><span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none">A
new delivery method using small extracellular vesicles (package of
molecules made by the cell) has emerged to deliver these silencing
molecules over a long distance and into target cells. In the lab of Dr.
Derrick Gibbings, it has been shown that these vehicles can provide
50-100% of the silencing molecules that they contain into the cells. It is
proposed that the membrane of the small extracellular vesicle and the
target cell's membrane will fuse using different proteins, and then the
contents will mix. Identifying these proteins required for the fusion will
aid in discovering a new cellular mechanism that can be manipulated to
improve the delivery of the treatments.</span><br align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"><br align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"><span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none">I
will be looking at different membrane proteins and seeing which ones are
vital in the fusion process of the membranes by finding genes that encode
for the protein and then shutting them off to see how that affects the
fusion. Ultimately, this will allow us to unravel the intricacies of the
fusion event, which will then provide the foundation in engineering these
small extracellular vesicles or any other delivery mechanisms to enhance
the delivery of therapeutics.</span></font>
</body>
</html>
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Valentino, Nicholas A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~